NOVN - ノバン (Novan Inc.) ノバン

 NOVNのチャート


 NOVNの企業情報

symbol NOVN
会社名 Novan Inc (ノバン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ノーバン(Novan Inc)は後期段階の医薬品会社である。同社は一酸化窒素プラットフォームを使用することによって治療法の開発・商業化に従事する。同社は調整可能な新規化学物質(NCEs)の操作を可能とするNitricil技術によって候補製品を開発する。同社の製剤サイエンスは非活性成分を使用することによって皮膚に応用される時に一酸化窒素の放出のさらなる調整を可能とする。同社は第3相尋常性座瘡の治療用SB204、第2相外生殖器・肛門疣贅の治療用製品候補SB206、皮膚・爪の真菌感染の治療用試験中局所的な抗真菌剤SB208を開発している。同社は炎症性皮膚疾患の治療用SB204を開発している。同社のパイプラインはまた局所的クリーム製品候補SB414を含む。   ノバンは米国の医薬品企業。主に臨床段階で、皮膚科の疾患に対する治療薬の開発・商業化に従事する。皮膚の免疫反応で不可欠な一酸化窒素を用いて治療するプラットフォ―ムを開発し、同社パイプラインには「SB206」、「SB208」、「SB414」などがある。本社はノ―スカロライナ州ダ―ラム。   Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men's and women's health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company's lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.
本社所在地 4105 Hopson Road Morrisville NC 27560 USA
代表者氏名 Robert A. Ingram ロバートA.イングラム
代表者役職名 Independent Chairman of the Board
電話番号 +1 919-485-8080
設立年月日 38718
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 59人
url www.novan.com
nasdaq_url https://www.nasdaq.com/symbol/novn
adr_tso
EBITDA EBITDA(百万ドル) -30.26500
終値(lastsale) 2.63
時価総額(marketcap) 68486362.46
時価総額 時価総額(百万ドル) 65.23131
売上高 売上高(百万ドル) 2.67800
企業価値(EV) 企業価値(EV)(百万ドル) 52.27231
当期純利益 当期純利益(百万ドル) -28.42800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novan Inc revenues increased 26% to $1.3M. Net loss decreased 40% to $12.8M. Revenues reflect License and collaboration revenue increase of 33% to $1.3M. Lower net loss reflects Change in fair value of warrant increase from $0K to $4.3M (income) General and administrative - Balancing decrease of 28% to $4.8M (expense) Research and Development - Balancing decrease of 10% to $11.8M (expense).

 NOVNのテクニカル分析


 NOVNのニュース

   Novan to Report Second Quarter 2021 Financial Results on August 12, 2021  2021/08/05 12:05:00 Intrado Digital Media
Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET
   Perspiring Stock: Netflix, Inc. (NASDAQ:NFLX), Novan, Inc. (NASDAQ:NOVN)  2021/08/01 21:18:16 Stock Equity
Netflix, Inc. (NFLX) with the stream of 0.65% also noticed, India Novan, Inc. (NOVN) encountered a rapid change of 5.35% in the last hour of trading session. Netflix, Inc. (NASDAQ:NFLX) The post Perspiring Stock: Netflix, Inc. (NASDAQ:NFLX), Novan, Inc. (NASDAQ:NOVN) appeared first on Stocks Equity .
   Novan completes patient visits in late-stage SB206 skin infection trial  2021/07/28 12:33:14 Seeking Alpha
   Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum  2021/07/28 12:05:00 Intrado Digital Media
Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less than 0.0001 and no serious adverse events related to treatment with SB206
   Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape  2021/07/27 00:00:00 Benzinga
Los Angeles, July 26, 2021 (GLOBE NEWSWIRE) -- Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape With a handful of novel therapies emerging this year, pharmaceuticals have a lot more potential to explore in the field of Genital Warts. DelveInsight''s Genital Warts Pipeline Insight, 2021'' report offers an exhaustive global coverage of the available marketed therapies, Genital Warts pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Genital Warts pipeline domain. Some of the major pointers taken from the Genital Warts Pipeline report: DelveInsight''s analysis presents Genital Warts Pipeline with 6+ active players in the domain investigating 6+ pipeline therapies . Major companies such as pHion Therapeutics, Orgenesis, KinoPharma, Novan, Cassiopeia, Innovax, Verrica Pharmaceuticals and others are developing potential drug candidates to improve the Genital Warts treatment scenario.
   Novan to Report Second Quarter 2021 Financial Results on August 12, 2021  2021/08/05 12:05:00 Intrado Digital Media
Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET
   Perspiring Stock: Netflix, Inc. (NASDAQ:NFLX), Novan, Inc. (NASDAQ:NOVN)  2021/08/01 21:18:16 Stock Equity
Netflix, Inc. (NFLX) with the stream of 0.65% also noticed, India Novan, Inc. (NOVN) encountered a rapid change of 5.35% in the last hour of trading session. Netflix, Inc. (NASDAQ:NFLX) The post Perspiring Stock: Netflix, Inc. (NASDAQ:NFLX), Novan, Inc. (NASDAQ:NOVN) appeared first on Stocks Equity .
   Novan completes patient visits in late-stage SB206 skin infection trial  2021/07/28 12:33:14 Seeking Alpha
   Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum  2021/07/28 12:05:00 Intrado Digital Media
Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less than 0.0001 and no serious adverse events related to treatment with SB206
   Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape  2021/07/27 00:00:00 Benzinga
Los Angeles, July 26, 2021 (GLOBE NEWSWIRE) -- Genital Warts Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Genital Warts Pipeline Landscape With a handful of novel therapies emerging this year, pharmaceuticals have a lot more potential to explore in the field of Genital Warts. DelveInsight''s Genital Warts Pipeline Insight, 2021'' report offers an exhaustive global coverage of the available marketed therapies, Genital Warts pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Genital Warts pipeline domain. Some of the major pointers taken from the Genital Warts Pipeline report: DelveInsight''s analysis presents Genital Warts Pipeline with 6+ active players in the domain investigating 6+ pipeline therapies . Major companies such as pHion Therapeutics, Orgenesis, KinoPharma, Novan, Cassiopeia, Innovax, Verrica Pharmaceuticals and others are developing potential drug candidates to improve the Genital Warts treatment scenario.
   Novartis-Aktie: Rückschlag  2021/06/12 20:00:18 BORSE ONLINE
Der Schweizer Pharmakonzern Novartis hat mehrere klinische Studien zu seinem Augenmedikament Beovu abgebrochen. Grund seien höhere Raten von intraokularen Entzündungen als bei der Vergleichstherapie. Von Sven Parplies, Euro am Sonntag
   Biosimilar of Remicade Market Future Trends, Revenue Growth, Profitability & Leading Players| Key players- Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), etc.  2021/06/12 09:00:41 Jumbo News
Biosimilar of Remicade Market to 2027: Deep Analysis The report offers a complete research study of the global Biosimilar of Remicade Market that includes accurate forecasts and analysis at global, regional, and country levels. It provides a comprehensive view of the global Biosimilar of Remicade Market and detailed value chain analysis to help players to []
   Glaucoma Treatment Market Current Status, In-depth Analysis and Forecast 2021-2026 : Novartis AG, Allergan, Merck & Co. Inc., Akorn Inc.  2021/06/12 02:30:51 Jumbo News
Pixion Market Research new study, Glaucoma Treatment Market Report 2021 provides an analytical assessment of the primary challenges faced by this market currently and in the coming years. The insights of the subject matter presented in the report will help market players in understanding the problems they may face while operating in this market over []
   The Buzz Show: Novan, Inc. (NASDAQ: NOVN) Surges Upon Announcement of Positive Preclinical Data  2021/06/11 20:42:29 Financial Buzz
FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Novan, Inc. Surges Upon Announcement of Positive Preclinical Data Novan, Inc. (NASDAQ: NOVN) surged over 60% in premarket trading after the company announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206 There are currently no U.S. The post The Buzz Show: Novan, Inc. (NASDAQ: NOVN) Surges Upon Announcement of Positive Preclinical Data first appeared on Financial Buzz .
   FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer  2021/06/11 18:07:09 US Food and Drug Administration
FDA granted accelerated approval to capmatinib (TABRECTATM, Novartis) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

 関連キーワード  (医薬品 米国株 ノバン NOVN Novan Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)